ArticleActa pharmaceutica Sinica. B2024
Colon-specific controlled release of oral liposomes for enhanced chemo-immunotherapy against colorectal cancer.
Article in Acta pharmaceutica Sinica. B, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Advances of oral micro- and nanomedicines for modulating intestinal barriers in the treatment of intestinal diseases.Acta pharmaceutica Sinica. B · 2026Review
- Harnessing chitosan-based biomaterials for advanced cancer immunotherapy: from nanocarriers to tumor microenvironment modulation.Journal of nanobiotechnology · 2026Review
- Oral hydrogel systems in lower gastrointestinal disorders: From disease-based therapy to microbiota-guided design.Materials today. Bio · 2026Review
- An orally administered biohybrid complex leveraging probiotic guidance to treat colorectal cancer viaMaterials today. Bio · 2026Article
- Chitosan-Functionalized Liposome-Mediated Fundus Delivery of Epigallocatechin-3-Gallate for Diabetic Retinopathy Therapy.Advanced healthcare materials · 2026Article
- Prodrug-integrated multifunctional liposome encapsulation enhances probiotic-based bacteriotherapy for inflammatory bowel disease.Materials today. Bio · 2026Article
- Modular design for drug delivery across hierarchical gastrointestinal barriers: From materials to systems.Materials today. Bio · 2026Review
- Biomolecular Interfaces in Targeted Nano-Drug Delivery: Molecular Recognition, Signaling Modulation, and Translational Pathways.Biomolecules · 2026Review
- Tumor-resident bacteria in gastrointestinal cancers: from regulatory mechanisms to clinical implications.Cancer biology & medicine · 2026Review
- Probiotic-drug co-delivery system enhances sulfasalazine activation for inflammatory bowel disease therapy.Materials today. Bio · 2026Article
- The Kv4.3 channel on c-low threshold mechanoreceptors in DRG is a key mediator transforming tactile stimuli into nociceptive signals in chemotherapy-induced neuropathy.Acta pharmaceutica Sinica. B · 2026Article
- Delivery Strategies and Clinical Significance of Oral Colon-targeted Drug Delivery Systems.AAPS PharmSciTech · 2026Review
- From bench to bowel: translating targeted drug delivery through gastrointestinal barriers.Frontiers in bioengineering and biotechnology · 2026Review
- Surface modification strategies of oral liposomes: functional design and barrier enhancement.Frontiers in pharmacology · 2026Review
- Oral Microcapsules Encapsulating Endometrial Regenerative Cell-Derived Exosomes Promote Intestinal Epithelial Barrier Repair and Ameliorate Experimental Colitis.International journal of nanomedicine · 2026Article
- Oral administration of probiotic spores-based biohybrid system for efficient attenuation of Salmonella Typhimurium-induced colitis.Journal of nanobiotechnology · 2025Article
- Novel therapeutic strategies and recent advances in gut microbiota synergy with nanotechnology for colorectal cancer treatment.Materials today. Bio · 2025Review
- Biosilicification-mimicking chiral nanostructures for targeted treatment of inflammatory bowel disease.Nature communications · 2025Article
- Emerging technologies and current challenges in intratumoral microbiota research.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A colon-specific drug delivery system has great potential for the oral administration of colorectal cancer. However, the uncontrollable
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.